Drug Trial Radar · NCT05016895
REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire
Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
767,535
Actual
Start
Aug 27, 2021
Primary completion
Jun 30, 2024
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- FHI 360Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, Ivory Coast
- First posted
- Aug 23, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 month, up to 11 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
REACH2 is a three-year implementation research study designed to examine the implementation through a mass drug administration platform of bi-annual single-dose azithromycin to reduce child mortality among children ages 1 to 11 months who reside in high child mortality settings.
Conditions
- Child Mortality
Interventions
Single-dose azithromycinDrug
Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- % of eligible population covered by interventionTime frame: three years
- Infant mortality rateTime frame: three years
- Implementation fidelityTime frame: three years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
FHI 360
Abidjan, Côte d’Ivoire
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.